Gravity-defying Sandoz; fundamental valuation metrics revisited
30/05/26 -"With Sandoz being a pioneer and amongst the handful of firms with true biosimilar development capability, manufacturing expertise in complex biosimilars and a robust commercial infrastructure, its ..."
Pages
55
Language
English
Published on
30/05/26
You may also be interested by these reports :
01/06/26
At a time when a lot of Big Pharmas are losing sleep because of looming patent expirations over the next five years, the likes of Sandoz (REDUCE; ...
30/05/26
With Sandoz being a pioneer and amongst the handful of firms with true biosimilar development capability, manufacturing expertise in complex ...
28/05/26
Backed by life cycle management of some of its key products, expansion into LatAm, a rebound of the animal healthcare business, and the recent ...
27/05/26
Our target price has been revised upwards, driven by multiple Phase III readouts anticipated in 2026, expansion of the late-stage pipeline, and the ...